Por: C V S Ram1 y A S Kumar. Journal of Human Hypertension (2014) 28, 699–704.
Severe hypertension (systolic blood pressure (BP) greater than or equal to160?mm?Hg) resistant to treatment with multiple antihypertensive medications, poses a serious challenge to therapeutic treatment. Catheter-based renal denervation (RDN) is being increasingly proposed and researched as a safe and effective method of treating this condition.
Por: Alexandre Persu, Eoin O’Brien y Paolo Verdecchia. Hypertension Research (2014) 37, 967–972.
Resistant hypertension as defined by the European Society of Hypertension and American Heart Association is a blood pressure that remains uncontrolled despite concomitant intake of at least three antihypertensive drugs (one of them preferably being a diuretic) at full doses. This definition is still based on office rather than out-of-office blood pressure measurement. In this review we propose a new, stricter definition of resistant hypertension based on ambulatory blood pressure measurement.
Resistant hypertension—complex mix of secondary causes and comorbidities. Por: T. Dudenbostel. Journal of Human Hypertension (2014) 28, 1–2.
Resistant hypertension (RHTN) is an increasingly common clinical problem1, 2 that studies have suggested is almost always heterogeneous in terms of etiology, risk factors and comorbidities. There has been a growing interest in defining epidemiology and pathophysiology in hope of identifying treatment targets. Ver más….
Estudios importantes sobre hipertension arterial de Cuba y el mundo
Resistant hypertension and target organ damage
Por: Maria Lorenza Muiesan, Massimo Salvetti, Damiano Rizzoni, Anna Paini, Claudia Agabiti-Rosei, Carlo Aggiusti and Enrico Agabiti Rosei. Hypertension Research (2013) 36, 485–491.
Cardiovascular (CV) complications such as myocardial infarction, heart failure, stroke and renal failure are related to both the degree and the duration of blood pressure (BP) increase. Resistant hypertension (RH) is associated with a higher risk of CV complications and a higher prevalence of target organ damage (TOD). The relationship between CV disease and TOD can be bidirectional. Elevated BP in RH may cause CV structural and functional alterations, and the development or persistence of left ventricular hypertrophy, aortic stiffness, atherosclerotic plaques, microvascular disease and renal dysfunction, may render hypertension more difficult to control. [Actualizado: 11 de junio de 2013]
Por: Adolfo Fontenla, José A. García-Donaire, Felipe Hernández, Julián Segura, Ricardo Salgado, César Cerezo, Luis M. Ruilope y Fernando Arribas. Rev Esp Cardiol. 2013;66:364-70 – Vol. 66 Núm.05.
La hipertensión resistente es un problema clínico por la dificultad de su tratamiento y el aumento de morbimortalidad que conlleva. Se ha demostrado que la denervación renal por catéter mejora el control de estos pacientes. Se describen los resultados de la creación de una unidad multidisciplinaria para la implementación de la denervación renal en el tratamiento de la hipertensión resistente.
La denervación renal implementada mediante un programa multidisciplinario ofrece una mejora en la presión arterial similar a la de estudios previos, con mayor reducción de fármacos antihipertensivos.
[Actualizado: 21 de mayo de 2013]
Comentarios recientes